JP2014526513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526513A5 JP2014526513A5 JP2014530821A JP2014530821A JP2014526513A5 JP 2014526513 A5 JP2014526513 A5 JP 2014526513A5 JP 2014530821 A JP2014530821 A JP 2014530821A JP 2014530821 A JP2014530821 A JP 2014530821A JP 2014526513 A5 JP2014526513 A5 JP 2014526513A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- liver
- residue
- reduction
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 9
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 7
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 210000004185 liver Anatomy 0.000 claims 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 4
- UNSKAUSCLTVFGO-KCDKBNATSA-N methyl (2s,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound COC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-KCDKBNATSA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- 102000007563 Galectins Human genes 0.000 claims 3
- 108010046569 Galectins Proteins 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 239000003833 bile salt Substances 0.000 claims 3
- 230000007882 cirrhosis Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 229920000140 heteropolymer Polymers 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 claims 1
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 101001096557 Dickeya dadantii (strain 3937) Rhamnogalacturonate lyase Proteins 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 102000000802 Galectin 3 Human genes 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000004378 Glycyrrhizin Substances 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 101000695838 Homo sapiens Receptor-type tyrosine-protein phosphatase U Proteins 0.000 claims 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 claims 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 230000010705 Peroxisome Proliferator-activated Receptor Activity Effects 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 102100036202 Serum amyloid P-component Human genes 0.000 claims 1
- 102000003929 Transaminases Human genes 0.000 claims 1
- 108090000340 Transaminases Proteins 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 claims 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 235000021466 carotenoid Nutrition 0.000 claims 1
- 150000001747 carotenoids Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 1
- 229940099500 cystamine Drugs 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940009976 deoxycholate Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims 1
- 229960004949 glycyrrhizic acid Drugs 0.000 claims 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims 1
- 235000019410 glycyrrhizin Nutrition 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000036796 hyperbilirubinemia Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229960003151 mercaptamine Drugs 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 238000001243 protein synthesis Methods 0.000 claims 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims 1
- 235000017700 silymarin Nutrition 0.000 claims 1
- 229960004245 silymarin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- -1 sisandra Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 230000008467 tissue growth Effects 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- 229960001661 ursodiol Drugs 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046001 vitamin b complex Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535655P | 2011-09-16 | 2011-09-16 | |
| US61/535,655 | 2011-09-16 | ||
| US201261656288P | 2012-06-06 | 2012-06-06 | |
| US61/656,288 | 2012-06-06 | ||
| PCT/US2012/055360 WO2013040324A1 (en) | 2011-09-16 | 2012-09-14 | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526513A JP2014526513A (ja) | 2014-10-06 |
| JP2014526513A5 true JP2014526513A5 (enExample) | 2015-11-12 |
| JP6185473B2 JP6185473B2 (ja) | 2017-08-23 |
Family
ID=47883762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530821A Active JP6185473B2 (ja) | 2011-09-16 | 2012-09-14 | 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130259870A1 (enExample) |
| EP (1) | EP2755480B1 (enExample) |
| JP (1) | JP6185473B2 (enExample) |
| KR (1) | KR101974675B1 (enExample) |
| CN (1) | CN103945695B (enExample) |
| AU (1) | AU2012308491B2 (enExample) |
| BR (1) | BR112014006220A2 (enExample) |
| CA (1) | CA2848711C (enExample) |
| ES (1) | ES2869884T3 (enExample) |
| IL (1) | IL231512B (enExample) |
| MX (1) | MX360979B (enExample) |
| WO (2) | WO2013040316A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| KR101968370B1 (ko) | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
| ES2848538T3 (es) | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| BR112015005772A2 (pt) * | 2012-09-17 | 2017-08-08 | Galectin Therapeutics Inc | método para a intensificação de imunoterapias específicas no tratamento de câncer |
| CA2924597A1 (en) | 2013-09-19 | 2015-03-26 | The Research Foundation For The State University Of New York | Methods and materials for treating diabetes or liver steatosis |
| US20170014446A1 (en) * | 2014-03-10 | 2017-01-19 | La Jolla Pharmaceutical Company | Compositions and methods for administering galectin antagonists |
| JP2017525702A (ja) * | 2014-08-18 | 2017-09-07 | ファーマジェネシス， インコーポレイテッド | ポリガラクツロナンラムノガラクツロナン（ｐｇｒｇ１）組成物 |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| BR112017018882A2 (pt) * | 2015-03-03 | 2018-04-17 | Kohjin Life Sciences Co Ltd | composição para aperfeiçoamento ou prevenção de uma doença de fígado gorduroso não alcoólico |
| WO2016160594A1 (en) | 2015-03-27 | 2016-10-06 | The Research Foundation For The State University Of New York | Methods and materials for reducing amyloid beta levels within a mammal |
| JP2018524274A (ja) | 2015-05-13 | 2018-08-30 | ディーエス バイオファーマ リミテッド | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| IL300476B2 (en) * | 2015-06-30 | 2024-07-01 | Eiger Group Int Inc | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
| WO2017109706A1 (en) * | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| MX394409B (es) * | 2016-03-04 | 2025-03-24 | Galectin Sciences Llc | Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos. |
| FR3050112B1 (fr) | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
| ES2966111T3 (es) * | 2016-06-03 | 2024-04-18 | Chemocentryx Inc | Pirrolo-piridinas y pirrolo-pirimidinas para su uso en el tratamiento de la fibrosis hepática |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| MX2019012086A (es) | 2017-04-14 | 2021-01-08 | Gelesis Llc | Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal. |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| WO2019010024A1 (en) * | 2017-07-04 | 2019-01-10 | The Regents Of The University Of California | METHODS OF TREATING LIVER DISEASES ASSOCIATED WITH INFLAMMATION OF DOOR SPACE OR PERIODAL INFLAMMATION |
| CN111183360B (zh) * | 2017-07-19 | 2024-10-18 | 生物辐射欧洲有限公司 | 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合 |
| GB201804922D0 (en) * | 2018-03-27 | 2018-05-09 | Ucl Business Plc | Traatment |
| JP2021529163A (ja) | 2018-06-29 | 2021-10-28 | グリコス バイオメディカル オーワイ | コンジュゲート |
| WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
| BR112022022737A2 (pt) * | 2020-05-22 | 2023-01-31 | Durect Corp | Tratamento de esteatose hepática não alcoólica (ehna) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4011285A1 (de) | 1990-04-06 | 1991-10-10 | Steigerwald Arzneimittelwerk | Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose |
| US6297229B1 (en) | 1994-11-14 | 2001-10-02 | Mayo Foundation For Medical Education And Research | Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis |
| US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
| US6180139B1 (en) | 1998-12-04 | 2001-01-30 | Viva America Marketing, Inc. | Composition and method for treating nonalcoholic steatohepatitis |
| WO2000062076A1 (en) * | 1999-04-13 | 2000-10-19 | Hsu Daniel K | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma |
| US6592910B1 (en) | 1999-04-20 | 2003-07-15 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
| CN1142272C (zh) | 2000-02-02 | 2004-03-17 | 中国人民解放军军事医学科学院百环生物医学研究中心 | 携带人肝细胞生长因子基因的重组腺病毒的用途 |
| CN100558407C (zh) * | 2000-02-04 | 2009-11-11 | 柳署弘 | 制备含有胆汁酸的澄清水溶液剂型 |
| US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
| BR0211336A (pt) | 2001-07-20 | 2004-09-28 | Intermune Inc | Métodos para o tratamento da fibrose do fìgado |
| US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| ATE555101T1 (de) | 2004-02-27 | 2012-05-15 | Asahi Kasei Pharma Corp | Neue benzothiazepin- und benzothiepinverbindungen |
| CA2582428A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| JP2008105945A (ja) | 2005-02-07 | 2008-05-08 | Ajinomoto Co Inc | アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物 |
| US7897583B2 (en) | 2005-05-24 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to PTPRU |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| ATE450526T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| US7897591B2 (en) * | 2005-07-28 | 2011-03-01 | Children's Medical Center Corporation | Method of treating fatty liver disease |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| JP5105297B2 (ja) | 2006-05-25 | 2012-12-26 | 味の素株式会社 | Ｐｐａｒ活性調節剤 |
| JP2009539885A (ja) | 2006-06-13 | 2009-11-19 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体 |
| US20080194575A1 (en) * | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| ES2417179T3 (es) | 2007-11-30 | 2013-08-06 | The Regents Of The University Of California | Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina |
| JP5302900B2 (ja) * | 2008-01-31 | 2013-10-02 | アステラス製薬株式会社 | 脂肪性肝疾患の治療用医薬組成物 |
| WO2009118343A1 (en) | 2008-03-27 | 2009-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for determining the occurrence of a liver disease in a subject |
| JPWO2009151116A1 (ja) | 2008-06-13 | 2011-11-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| US20110313276A1 (en) * | 2008-11-18 | 2011-12-22 | Centre Hospitalier Universitaire D'angers | Non-invasive in vitro method for quantifying liver lesions |
| JP2010229099A (ja) * | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
| WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| KR101968370B1 (ko) * | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
-
2012
- 2012-09-14 JP JP2014530821A patent/JP6185473B2/ja active Active
- 2012-09-14 US US13/573,436 patent/US20130259870A1/en not_active Abandoned
- 2012-09-14 MX MX2014003213A patent/MX360979B/es active IP Right Grant
- 2012-09-14 WO PCT/US2012/055348 patent/WO2013040316A1/en not_active Ceased
- 2012-09-14 CA CA2848711A patent/CA2848711C/en active Active
- 2012-09-14 AU AU2012308491A patent/AU2012308491B2/en active Active
- 2012-09-14 ES ES12831657T patent/ES2869884T3/es active Active
- 2012-09-14 WO PCT/US2012/055360 patent/WO2013040324A1/en not_active Ceased
- 2012-09-14 EP EP12831657.7A patent/EP2755480B1/en active Active
- 2012-09-14 US US13/573,454 patent/US8658787B2/en active Active
- 2012-09-14 BR BR112014006220A patent/BR112014006220A2/pt not_active Application Discontinuation
- 2012-09-14 KR KR1020147009796A patent/KR101974675B1/ko active Active
- 2012-09-14 CN CN201280049079.6A patent/CN103945695B/zh active Active
-
2014
- 2014-03-13 IL IL231512A patent/IL231512B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526513A5 (enExample) | ||
| Oh et al. | Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling | |
| Sanchez-Gonzalez et al. | Differential effect of quercetin on cisplatin-induced toxicity in kidney and tumor tissues | |
| ES2877326T3 (es) | Composiciones que comprenden un sulforafano y extracto o polvo de cardo mariano | |
| JP2015522561A5 (enExample) | ||
| AU2007281038B2 (en) | Methods and compositions for inhibiting angiogenesis | |
| ES2848538T3 (es) | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible | |
| KR102067848B1 (ko) | 섬유증의 치료 방법 | |
| CN110536683A (zh) | 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合 | |
| EP3307265B1 (en) | Pharmaceutical combination and uses thereof | |
| Li et al. | Combination of curcumin and piperine prevents formation of gallstones in C57BL6 mice fed on lithogenic diet: whether NPC1L1/SREBP2 participates in this process? | |
| JP2009530398A5 (enExample) | ||
| CA3132637A1 (en) | Cannabinoid acid ester compositions and uses thereof | |
| CA3035875A1 (en) | Compounds for treatment of lipoprotein metabolism disorders | |
| JP2025032212A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| Lee et al. | Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate | |
| TW201117805A (en) | Heparanase-activity inhibitor, wrinkle ameliorating agent containing same, and pharmaceutical composition | |
| CN105497895A (zh) | 基于paqr3的降低胆固醇、脂肪合成的方法 | |
| RS53546B1 (sr) | Kompozicija za inhibiranje inflamacije koja se sastoji od hijaluronske kiseline i inhibitora hmg-coa reduktaze | |
| US12337024B2 (en) | Larazotide formulations | |
| JP2020516622A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| RU2491065C2 (ru) | Фармацевтическая композиция, содержащая производное 1,2-дитиолтиона, для предотвращения или лечения заболевания, обусловленного повышенной экспрессией lxr-альфа | |
| EP4477234A1 (en) | Cancer-cell proliferation inhibitor and cancer-cell-proliferation inhibition enhancer | |
| WO2003074084A1 (en) | A pharmaceutical composition | |
| CN115361942A (zh) | 药物组合物及其抑制膜ace2表达的用途 |